Participatory Research for Fine-tuning of a 2.0 System to Optimise Home Management of Oral Cancer Therapies.
Cancer, Oral Drug Administration
About this trial
This is an interventional health services research trial for Cancer focused on measuring cancer, oral drug, sunitinib, capecitabine, mobile app
Eligibility Criteria
Inclusion Criteria:
- ECOG-Performance Status (PS) less or equal to 1;
- life expectancy > 12 weeks;
- candidate for treatment with capecitabine or sunitinib as monotherapy (adjuvant and advanced settings allowed);
- clear understanding of the Italian language;
- subjects who are, in the opinion of the Investigator, able to understand this study, to cooperate with the study procedures and able to manage mobile devices after basic training course held at baseline;
- written informed consent
Exclusion Criteria:
- Patients receiving also intravenous anticancer treatment
Sites / Locations
- Azienda Ospedaliera Papa Giovanni XXIII, Bergamo
- Irst-Irccs
- Azienda Provinciale per i Servizi Sanitari della Provincia Autonoma di Trento
Arms of the Study
Arm 1
Experimental
Cancer patients undergoing oral therapy
At the time of therapy prescription, patients candidate for oral therapy with capecitabine or sunitinib will be provided with informations on the side-effects of therapy and on the use and functions of the mobile diary app TreC-Onco. Patients are required to manually insert data into the mobile diary app at least once a day. Patients will be visited every 6 weeks. During the visit, the clinician will compare adherence and toxicity data entered into the mobile diary app with those directly reported by the patient and by drug accountability.